Company news
Poolbeg Pharma PLC news in 2023
Poolbeg Pharma PLC's news releases, calls and decks from 2023, newest first.
RSV AI Drug Candidate Analysis Update
December 20, 2023
Poolbeg Pharma plc - POLB 001 Data Presented at ASH
December 12, 2023
POLB 001 Data Presented at ASH
December 11, 2023
Directorate Change
November 30, 2023
Poolbeg Pharma plc - Immunomodulator II patent granted in Japan
November 22, 2023
Immunomodulator II patent granted in Japan
November 21, 2023
Poolbeg Pharma plc - POLB 001 LPS Challenge Trial Data to be presented at IUIS
November 17, 2023
POLB 001 LPS Trial Data to be Presented at IUIS
November 16, 2023
Former Amryt Pharma Leadership Team join Poolbeg
November 9, 2023
POLB001 Data to be Presented at ASH Annual Meeting
November 3, 2023
POLB 001 Oncology Programme Update Meeting
November 1, 2023
SAB Endorses Influenza Drug Targets
October 26, 2023
Poolbeg Partners with a Nasdaq-Listed Biopharma
October 17, 2023
Favourable Conclusion of Patent Opposition
September 29, 2023
Immunomodulator I Patent Portfolio Strengthened
September 20, 2023
Immunomodulator I Patent Opposition Withdrawal
September 19, 2023
Interim results for the six months to 30 June 2023
September 13, 2023
AI led programme identifies influenza drug targets
June 29, 2023
Oral Vaccine Programme Moves Forward
June 22, 2023
Board Appointment
May 24, 2023
Results of Annual General Meeting
May 11, 2023
Results for the year ended 31 December 2022
March 30, 2023
POLB 001 patent portfolio strengthened
March 8, 2023
Second Price Monitoring Extn
March 2, 2023
Price Monitoring Extension
March 2, 2023
Positive Results POLB001 LPS Human Challenge Trial
March 2, 2023
Strategic expansion of POLB 001 into oncology
January 16, 2023
Positive Initial Data Analysis in POLB 001 Trial
January 9, 2023
Calls in 2023
Decks in 2023
- Investor Presentation (July 2023)
Investor deck · 28 slides · July 2023